570 related articles for article (PubMed ID: 30898544)
1. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
2. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
3. Sugar-based colloidal nanocarriers for topical meglumine antimoniate application to cutaneous leishmaniasis treatment: Ex vivo cutaneous retention and in vivo evaluation.
Aragão Horoiwa T; Cortez M; Sauter IP; Migotto A; Bandeira CL; Cerize NNP; de Oliveira AM
Eur J Pharm Sci; 2020 Apr; 147():105295. PubMed ID: 32145429
[TBL] [Abstract][Full Text] [Related]
4. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
5. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
[TBL] [Abstract][Full Text] [Related]
6. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR
Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698
[TBL] [Abstract][Full Text] [Related]
7. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
Bemani E; Oryan A; Bahrami S
Exp Parasitol; 2019 Oct; 205():107747. PubMed ID: 31442454
[TBL] [Abstract][Full Text] [Related]
9. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice.
Jaafari MR; Bavarsad N; Bazzaz BS; Samiei A; Soroush D; Ghorbani S; Heravi MM; Khamesipour A
Antimicrob Agents Chemother; 2009 Jun; 53(6):2259-65. PubMed ID: 19223613
[TBL] [Abstract][Full Text] [Related]
10. Study of the
Azadi R; Alipour-Talesh G; Yazdanpanah MJ; Alavizadeh SH; Maleki M; Banihashemi M; Jaafari MR
J Vector Borne Dis; 2020; 57(1):78-84. PubMed ID: 33818460
[TBL] [Abstract][Full Text] [Related]
11. Leishmanicidal potentials of
Sharifi F; Sharififar F; Pournamdari M; Ansari M; Tavakoli Oliaee R; Bamorovat M; Khosravi A; Keyhani AR; Salarkia E; Mortazaeizdeh A; Dabiri S; Khamesipour A; Sharifi I
J Med Microbiol; 2021 Jun; 70(6):. PubMed ID: 34115583
[No Abstract] [Full Text] [Related]
12. The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.
Gonçalves-Oliveira LF; Souza-Silva F; de Castro Côrtes LM; Veloso LB; Santini Pereira BA; Cysne-Finkelstein L; Lechuga GC; Bourguignon SC; Almeida-Souza F; da Silva Calabrese K; Ferreira VF; Alves CR
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():101-108. PubMed ID: 31430693
[TBL] [Abstract][Full Text] [Related]
13. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis.
Ferreira FM; Castro RA; Batista MA; Rossi FM; Silveira-Lemos D; Frézard F; Moura SA; Rezende SA
Parasitol Res; 2014 Feb; 113(2):533-43. PubMed ID: 24292604
[TBL] [Abstract][Full Text] [Related]
14. Topical tamoxifen in the therapy of cutaneous leishmaniasis.
Trinconi CT; Reimão JQ; Bonano VI; Espada CR; Miguel DC; Yokoyama-Yasunaka JKU; Uliana SRB
Parasitology; 2018 Apr; 145(4):490-496. PubMed ID: 28274283
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis.
Borborema SET; Osso Junior JA; Tempone AG; de Andrade Junior HF; do Nascimento N
Biomed Pharmacother; 2018 Jul; 103():1609-1616. PubMed ID: 29864949
[TBL] [Abstract][Full Text] [Related]
16. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
17. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
[TBL] [Abstract][Full Text] [Related]
18. Naloxone Effects Against Cutaneous Leishmaniasis Caused by
Azizi H; Mahdavinik E; Hataminejad M; Khamesipour A; Montazeri S
Infect Disord Drug Targets; 2023; 23(6):e020623217598. PubMed ID: 37278044
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
20. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
